Global Hereditary Cancer Testing Market Report (2025–2036)
Market Overview
The global hereditary cancer testing market was valued at USD xxxx million in 2025 and is projected to reach USD xxxx million by 2036, growing at a CAGR of xx%. Hereditary cancer testing involves analyzing DNA and RNA to identify genetic mutations that predispose individuals to cancers such as breast, gastrointestinal, prostate, and lung cancers. Rising awareness of genetic risk factors, advancements in next-generation sequencing (NGS), and increasing adoption of personalized medicine are driving market growth.
Impact of COVID-19
The pandemic disrupted diagnostic services and delayed elective testing in 2020. However, it accelerated telemedicine adoption and highlighted the importance of preventive healthcare. Post-COVID, demand for hereditary cancer testing has rebounded strongly, supported by digital health platforms, at-home sample collection kits, and growing awareness of genetic predisposition.
Market Segmentation
By Type
- RNA Testing – used for gene expression profiling and mutation detection.
- DNA Testing – widely adopted for identifying inherited mutations in BRCA1, BRCA2, and other cancer-related genes.
- Comprehensive Genomic Profiling – multi-gene panels for broader risk assessment.
- Single-Gene Testing – targeted analysis for specific hereditary cancers.
By Application
- Breast Cancer – BRCA1/2 and other gene mutations.
- Gastrointestinal Cancer – Lynch syndrome and colorectal cancer risk.
- Prostate Cancer – genetic predisposition testing for early detection.
- Respiratory/Lung Cancer – hereditary risk profiling.
- Other Cancers – ovarian, pancreatic, and rare hereditary cancers.
Regional Analysis
- North America: Largest market; strong demand driven by awareness campaigns, advanced healthcare infrastructure, and reimbursement support.
- Europe: Significant growth; Germany, U.K., and France lead adoption with strong regulatory frameworks and genetic counseling services.
- Asia-Pacific: Fastest-growing region; China, India, and Japan expanding genetic testing services through rising healthcare investments.
- South America: Brazil and Argentina showing growth in preventive healthcare and oncology diagnostics.
- Middle East & Africa: Emerging demand; increasing investments in healthcare infrastructure and awareness programs.
Key Players
- Ambry Genetics (Konica Minolta)
- Asper Biogene
- Natera Inc.
- Caris Life Sciences
- BioReference Laboratories (GeneDx)
- LabSolutions
- Progenity Inc.
- ARUP Laboratories
- NeoGenomics Inc.
- Blueprint Genetics
- CellMax Life
- Fulgent Genetics
- Myriad Genetics
- Myogenes
- LabCorp
- Quest Diagnostics
- Pathway Genomics
- Strand Life Sciences
Additional Players:
- Invitae Corporation (U.S.)
- Color Genomics (U.S.)
- Guardant Health (U.S.)
- Roche Diagnostics (Switzerland)
- Illumina Inc. (U.S.)
- Thermo Fisher Scientific (U.S.)
- Genomic Health (Exact Sciences, U.S.)
- BGI Genomics (China)
Porter’s Five Forces
- Threat of New Entrants – Moderate; requires advanced technology, regulatory approvals, and brand trust.
- Bargaining Power of Suppliers – Moderate; reagents and sequencing platforms are specialized.
- Bargaining Power of Buyers – High; patients and healthcare providers demand affordability and accuracy.
- Threat of Substitutes – Moderate; alternatives include imaging and conventional diagnostics.
- Industry Rivalry – High; global players compete on innovation, pricing, and service accessibility.
SWOT Analysis
Strengths:
- Critical role in preventive oncology
- Strong demand for personalized medicine
- Established global players with advanced technology
Weaknesses:
- High testing costs
- Limited awareness in emerging markets
- Dependence on reimbursement policies
Opportunities:
- Expansion in Asia-Pacific and Middle East markets
- Growth in at-home genetic testing kits
- Rising demand for multi-gene panel testing
Threats:
- Regulatory hurdles and ethical concerns
- Competition from alternative diagnostic methods
- Data privacy and genetic information security risks
Trend Analysis
- At-Home Testing Kits: Growing adoption of direct-to-consumer genetic testing.
- Multi-Gene Panels: Comprehensive risk assessment gaining traction.
- Digital Health Integration: Telemedicine and online genetic counseling.
- AI & Bioinformatics: Advanced analytics for mutation interpretation.
- Preventive Healthcare Growth: Rising focus on early detection and risk management.
Drivers & Challenges
Drivers:
- Rising prevalence of hereditary cancers
- Increasing awareness of genetic predisposition
- Technological advancements in sequencing and bioinformatics
- Expansion of personalized medicine
Challenges:
- High costs and limited reimbursement in some regions
- Ethical concerns over genetic data usage
- Limited access in low-income countries
- Need for skilled genetic counselors
Value Chain Analysis
- Raw Materials: Reagents, sequencing platforms, and consumables.
- Testing Services: DNA/RNA extraction, sequencing, and mutation analysis.
- Distribution: Hospitals, diagnostic labs, and direct-to-consumer platforms.
- End Users: Patients, oncologists, genetic counselors, and research institutions.
- After-Sales Services: Genetic counseling, data interpretation, and preventive healthcare programs.
Quick Recommendations for Stakeholders
- Manufacturers: Invest in affordable, multi-gene panel testing solutions.
- Healthcare Providers: Expand genetic counseling services to support patients.
- Policy Makers: Strengthen reimbursement frameworks and regulate genetic data privacy.
- Investors: Focus on Asia-Pacific and Europe for high-growth opportunities.
- Consumers: Leverage hereditary cancer testing for preventive healthcare and informed decision-making.
Explore more reports here-
https://westernmarketresearch.com/reports
1. Market Overview of Hereditary Cancer Testing
1.1 Hereditary Cancer Testing Market Overview
1.1.1 Hereditary Cancer Testing Product Scope
1.1.2 Market Status and Outlook
1.2 Hereditary Cancer Testing Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Hereditary Cancer Testing Historic Market Size by Regions
1.4 Hereditary Cancer Testing Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Hereditary Cancer Testing Sales Market by Type
2.1 Global Hereditary Cancer Testing Historic Market Size by Type
2.2 Global Hereditary Cancer Testing Forecasted Market Size by Type
2.3 RNA Testing
2.4 DNA Testing
3. Covid-19 Impact Hereditary Cancer Testing Sales Market by Application
3.1 Global Hereditary Cancer Testing Historic Market Size by Application
3.2 Global Hereditary Cancer Testing Forecasted Market Size by Application
3.3 Breast Cancer
3.4 Gastrointestinal Cancer
3.5 Prostate Cancer
3.6 Respiratory/Lung Cancer
3.7 Other Cancers
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Hereditary Cancer Testing Production Capacity Market Share by Manufacturers
4.2 Global Hereditary Cancer Testing Revenue Market Share by Manufacturers
4.3 Global Hereditary Cancer Testing Average Price by Manufacturers
5. Company Profiles and Key Figures in Hereditary Cancer Testing Business
5.1 Ambry Genetics (Konica Minota)
5.1.1 Ambry Genetics (Konica Minota) Company Profile
5.1.2 Ambry Genetics (Konica Minota) Hereditary Cancer Testing Product Specification
5.1.3 Ambry Genetics (Konica Minota) Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.2 Asper Biogene
5.2.1 Asper Biogene Company Profile
5.2.2 Asper Biogene Hereditary Cancer Testing Product Specification
5.2.3 Asper Biogene Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.3 Natera
5.3.1 Natera Company Profile
5.3.2 Natera Hereditary Cancer Testing Product Specification
5.3.3 Natera Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.4 Caris Life Sciences
5.4.1 Caris Life Sciences Company Profile
5.4.2 Caris Life Sciences Hereditary Cancer Testing Product Specification
5.4.3 Caris Life Sciences Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.5 BioReference Laboratories (GeneDx)
5.5.1 BioReference Laboratories (GeneDx) Company Profile
5.5.2 BioReference Laboratories (GeneDx) Hereditary Cancer Testing Product Specification
5.5.3 BioReference Laboratories (GeneDx) Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.6 LabSolutions
5.6.1 LabSolutions Company Profile
5.6.2 LabSolutions Hereditary Cancer Testing Product Specification
5.6.3 LabSolutions Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.7 Progenity?Inc
5.7.1 Progenity?Inc Company Profile
5.7.2 Progenity?Inc Hereditary Cancer Testing Product Specification
5.7.3 Progenity?Inc Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.8 ARUP Laboratories
5.8.1 ARUP Laboratories Company Profile
5.8.2 ARUP Laboratories Hereditary Cancer Testing Product Specification
5.8.3 ARUP Laboratories Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.9 NeoGenomics
5.9.1 NeoGenomics Company Profile
5.9.2 NeoGenomics Hereditary Cancer Testing Product Specification
5.9.3 NeoGenomics Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.10 Blueprint Genetics
5.10.1 Blueprint Genetics Company Profile
5.10.2 Blueprint Genetics Hereditary Cancer Testing Product Specification
5.10.3 Blueprint Genetics Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.11 CellMax Life
5.11.1 CellMax Life Company Profile
5.11.2 CellMax Life Hereditary Cancer Testing Product Specification
5.11.3 CellMax Life Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.12 Fulgent Genetics
5.12.1 Fulgent Genetics Company Profile
5.12.2 Fulgent Genetics Hereditary Cancer Testing Product Specification
5.12.3 Fulgent Genetics Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.13 Myriad Genetics
5.13.1 Myriad Genetics Company Profile
5.13.2 Myriad Genetics Hereditary Cancer Testing Product Specification
5.13.3 Myriad Genetics Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.14 Myogenes
5.14.1 Myogenes Company Profile
5.14.2 Myogenes Hereditary Cancer Testing Product Specification
5.14.3 Myogenes Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.15 LabCorp
5.15.1 LabCorp Company Profile
5.15.2 LabCorp Hereditary Cancer Testing Product Specification
5.15.3 LabCorp Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.16 Quest Diagnostics
5.16.1 Quest Diagnostics Company Profile
5.16.2 Quest Diagnostics Hereditary Cancer Testing Product Specification
5.16.3 Quest Diagnostics Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.17 Pathway Genomics
5.17.1 Pathway Genomics Company Profile
5.17.2 Pathway Genomics Hereditary Cancer Testing Product Specification
5.17.3 Pathway Genomics Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
5.18 Strand Life Sciences
5.18.1 Strand Life Sciences Company Profile
5.18.2 Strand Life Sciences Hereditary Cancer Testing Product Specification
5.18.3 Strand Life Sciences Hereditary Cancer Testing Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Hereditary Cancer Testing Market Size
6.2 North America Hereditary Cancer Testing Key Players in North America
6.3 North America Hereditary Cancer Testing Market Size by Type
6.4 North America Hereditary Cancer Testing Market Size by Application
7. East Asia
7.1 East Asia Hereditary Cancer Testing Market Size
7.2 East Asia Hereditary Cancer Testing Key Players in North America
7.3 East Asia Hereditary Cancer Testing Market Size by Type
7.4 East Asia Hereditary Cancer Testing Market Size by Application
8. Europe
8.1 Europe Hereditary Cancer Testing Market Size
8.2 Europe Hereditary Cancer Testing Key Players in North America
8.3 Europe Hereditary Cancer Testing Market Size by Type
8.4 Europe Hereditary Cancer Testing Market Size by Application
9. South Asia
9.1 South Asia Hereditary Cancer Testing Market Size
9.2 South Asia Hereditary Cancer Testing Key Players in North America
9.3 South Asia Hereditary Cancer Testing Market Size by Type
9.4 South Asia Hereditary Cancer Testing Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Hereditary Cancer Testing Market Size
10.2 Southeast Asia Hereditary Cancer Testing Key Players in North America
10.3 Southeast Asia Hereditary Cancer Testing Market Size by Type
10.4 Southeast Asia Hereditary Cancer Testing Market Size by Application
11. Middle East
11.1 Middle East Hereditary Cancer Testing Market Size
11.2 Middle East Hereditary Cancer Testing Key Players in North America
11.3 Middle East Hereditary Cancer Testing Market Size by Type
11.4 Middle East Hereditary Cancer Testing Market Size by Application
12. Africa
12.1 Africa Hereditary Cancer Testing Market Size
12.2 Africa Hereditary Cancer Testing Key Players in North America
12.3 Africa Hereditary Cancer Testing Market Size by Type
12.4 Africa Hereditary Cancer Testing Market Size by Application
13. Oceania
13.1 Oceania Hereditary Cancer Testing Market Size
13.2 Oceania Hereditary Cancer Testing Key Players in North America
13.3 Oceania Hereditary Cancer Testing Market Size by Type
13.4 Oceania Hereditary Cancer Testing Market Size by Application
14. South America
14.1 South America Hereditary Cancer Testing Market Size
14.2 South America Hereditary Cancer Testing Key Players in North America
14.3 South America Hereditary Cancer Testing Market Size by Type
14.4 South America Hereditary Cancer Testing Market Size by Application
15. Rest of the World
15.1 Rest of the World Hereditary Cancer Testing Market Size
15.2 Rest of the World Hereditary Cancer Testing Key Players in North America
15.3 Rest of the World Hereditary Cancer Testing Market Size by Type
15.4 Rest of the World Hereditary Cancer Testing Market Size by Application
16 Hereditary Cancer Testing Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter
Market Segmentation
By Type
- RNA Testing – used for gene expression profiling and mutation detection.
- DNA Testing – widely adopted for identifying inherited mutations in BRCA1, BRCA2, and other cancer-related genes.
- Comprehensive Genomic Profiling – multi-gene panels for broader risk assessment.
- Single-Gene Testing – targeted analysis for specific hereditary cancers.
By Application
- Breast Cancer – BRCA1/2 and other gene mutations.
- Gastrointestinal Cancer – Lynch syndrome and colorectal cancer risk.
- Prostate Cancer – genetic predisposition testing for early detection.
- Respiratory/Lung Cancer – hereditary risk profiling.
- Other Cancers – ovarian, pancreatic, and rare hereditary cancers.
Regional Analysis
- North America: Largest market; strong demand driven by awareness campaigns, advanced healthcare infrastructure, and reimbursement support.
- Europe: Significant growth; Germany, U.K., and France lead adoption with strong regulatory frameworks and genetic counseling services.
- Asia-Pacific: Fastest-growing region; China, India, and Japan expanding genetic testing services through rising healthcare investments.
- South America: Brazil and Argentina showing growth in preventive healthcare and oncology diagnostics.
- Middle East & Africa: Emerging demand; increasing investments in healthcare infrastructure and awareness programs.
Key Players
- Ambry Genetics (Konica Minolta)
- Asper Biogene
- Natera Inc.
- Caris Life Sciences
- BioReference Laboratories (GeneDx)
- LabSolutions
- Progenity Inc.
- ARUP Laboratories
- NeoGenomics Inc.
- Blueprint Genetics
- CellMax Life
- Fulgent Genetics
- Myriad Genetics
- Myogenes
- LabCorp
- Quest Diagnostics
- Pathway Genomics
- Strand Life Sciences
